Life Extension Skin Care Sale

Hepatitis B


A.D.A.M Editorial Board.Hepatitis B. Pubmed Health. 2010; Available at: [Accessed August 26, 2012]

Abediankenari, S., Ghasemi, M., Nasehi, M. M., Abedi, S., and Hosseini, V. Determination of trace elements in patients with chronic hepatitis B. Acta Med Iran. 2011;49(10):667–9

Abenavoli, L., Capasso, R., Milic, N., and Capasso, F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–32

Balamtekin, N., Kurekci, A. E., Atay, A., Plasma levels of trace elements have an implication on interferon treatment of children with chronic hepatitis B infection. Biological Trace Element Research. 2010;135(1-3):153–61

Billioud, G., Pichoud, C., Puerstinger, G., Neyts, J., and Zoulim, F. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res. 2011;92(2):271–6

Borsari, M., Gabbi, C., Ghelfi, F., et al. Silybin, a new iron-chelating agent. J. Inorg. Biochem. 2001;85(2-3):123–9

Bravi, F., Bosetti, C., Tavani, A., et al. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology. 2007;46(2):430–5

Brock, J. H. Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch. Dis. Child. 1980;55(6):417–21

Buzzelli, G., Moscarella, S., Giusti, A., Duchini, A., Marena, C., and Lampertico, M.A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis.Int J ClinPharmacolTherToxicol. 1993;31(9):456–60

Byrd KK, Murphy TV, and Hu DJ. MD Consult. DNA Viruses: Hepadnaviridae. In: Long: Principles and Practice of Pediatric Infectious Diseases, 4th ed. 2012. Available at: Accessed September 21, 2012.

Castera, L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142(6):1293–4

Centers for Disease Control and Prevention (CDC). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1–25

Centers for Disease Control and Prevention (CDC).Availability of hepatitis B vaccine that does not contain thimerosal as a preservative.MMWR Morb.Mortal. Wkly. Rep. 1999;48(35):780–2

Centers for Disease Control and Prevention (CDC).Hepatitis. MMWR Recomm Rep. 1990;39(RR-2):1–22.

Centers for Disease Control and Prevention (CDC).Immunization of adolescents. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep. 1996;45(RR-13):1–16

Chen, C.-J., Yang, H.-I., Su, J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.JAMA. 2006;295(1):65–73

Chevaliez, S., Rodriguez, C., and Pawlotsky, J.-M.New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142(6):1303–1313.e1

Chien, R.-N., Lin, C.-Y., Yeh, C.-T., and Liaw, Y.-F. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. J. Viral Hepat. 2006;13(12):845–50

Cui, X., Wang, Y., Kokudo, N., Fang, D., and Tang, W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection.Biosci Trends. 2010;4(2):39–47

Dang, S.-S., Jia, X.-L., Song, P., et al. Inhibitory effect of emodin and Astragalus polysaccharide on the replication of HBV.World J Gastroenterol. 2009;15(45):5669–73

Daniels, D., Grytdal, S., Wasley, A., Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis - United States, 2007.MMWR SurveillSumm. 2009;58(3):1–27

Delaney, W., Bartholomeusz, A., and Locarnini, S. A. Evolving therapies for the treatment of chronic hepatitis B virus infection.Expert OpinInvestig Drugs. 2002;11(2):169–87

Deres, K., Schröder, C. H., Paessens, A., et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 2003;299(5608):893–6

Duygu, F., Karsen, H., Aksoy, N., and Taskin, A. Relationship of Oxidative Stress in Hepatitis B Infection Activity with HBV DNA and Fibrosis. Ann Lab Med. 2012;32(2):113

El-Serag, H. B. Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterology. 2012;142(6):1264–1273.e1

Fiorino, S., Conti, F., Gramenzi, A., et al. Vitamins in the treatment of chronic viral hepatitis.Br J Nutr. 2011;105(7):982–9

Garcia-Tsao, G., Lim, J. K., Lim, J., Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104(7):1802–29

Gish, R. G., Satishchandran, C., Young, M., and Pachuk, C. RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study. Antivir.Ther.(Lond.). 2011;16(4):547–54

Gish, R., Jia, J.-D., Locarnini, S., and Zoulim, F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12(4):341–53

Gitlin, N. Hepatitis B: diagnosis, prevention, and treatment. Clin Chem. 1997;43(8 Pt 2):1500–6

Grimm, D., and Thimme, R. Hepatology International, Volume 5, Number 2 - SpringerLink. Hepatol Int. 2011;

Gunduz, H., Karabay, O., Tamer, A., Ozaras, R., Mert, A., and Tabak, O. F. N-acetyl cysteine therapy in acute viral hepatitis.World J Gastroenterol. 2003;9(12):2698–700

Hara, K., Ikeda, M., Saito, S., et al. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol. Res. 2002;24(3):228

He, W., Li, L.-X., Liao, Q.-J., Liu, C.-L., and Chen, X.-L.Epigallocatechingallate inhibits HBV DNA synthesis in a viral replication - inducible cell line. World J Gastroenterol. 2011;17(11):1507–14

Hou, J., Liu, Z., and Gu, F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):50–7

Ichai, P., and Samuel, D. Epidemiology of liver failure.Clin Res HepatolGastroenterol. 2011;35(10):610–7

Inoue, M., Kurahashi, N., Iwasaki, M., et al. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1746–53

Ioannou, G. N. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med. 2011;154(5):319–28

Kang, X., Xie, Q., Zhou, X., et al. Effects of hepatitis B virus S protein exposure on sperm membrane integrity and functions.PLoS ONE. 2012;7(3):e33471

Khan, M. S., Dilawar, S., Ali, I., and Rauf, N.The possible role of selenium concentration in hepatitis B and C patients.Saudi J Gastroenterol. 2012;18(2):106–10

Kim, H. J., Yoo, H. S., Kim, J. C., et al. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication. J Ethnopharmacol. 2009;124(2):189–96

Kuloğlu, Z., Kırbaş, G., Erden, E., and Kansu, A. Interferon-alpha-2a and zinc combination therapy in children with chronic hepatitis B infection.Biological Trace Element Research. 2011;143(3):1302–9

Ladak, F., Gjelsvik, A., Feller, E., Rosenthal, S., and Montague, B. T. Hepatitis B in the United States: ongoing missed opportunities for hepatitis B vaccination, evidence from the Behavioral Risk Factor Surveillance Survey, 2007. Infection. 2012;40(4):405–13

Larsson, S. C., and Wolk, A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology. 2007;132(5):1740–5

Lee HC. Acute liver failure related to hepatitis B virus. Hepatologyresearch : the official journal of the Japan Society of Hepatology. Nov 2008;38Suppl 1:S9-S13.

Lee, C., Gong, Y., Brok, J., Boxall, E. H., and Gluud, C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006;(2):CD004790

Leung, W. W.-M., Ho, S. C., Chan, H. L. Y., Wong, V., Yeo, W., and Mok, T. S. K. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case-control study. Journal of Epidemiology & Community Health. 2011;65(6):556–8

Li, S., Zhou, H., Huang, G., and Liu, N. Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin. Med. Microbiol. Immunol. 2009;198(1):19–25

Li, Y., Chang, S.-C., Goldstein, B. Y., et al. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol. 2011;35(4):362–8

Liaw, Y. F., and Chu, C.-M.Hepatitis B virus infection.Lancet. 2009;373(9663):582–92

Lin MC, Wu CC, Cheng SB, Liu TJ, P'Eng F K. The influence of high serum testosterone levels on the long-term prognosis in male patients undergoing hepatectomy for early stage hepatocellular carcinoma without vascular invasion. World journal of surgery.Jul 2007;31(7):1469-1473.

Lin, C.-C., Liu, W.-H., Wang, Z.-H., and Yin, M.-C.Vitamins B status and antioxidative defense in patients with chronic hepatitis B or hepatitis C virus infection.Eur J Nutr. 2011;50(7):499–506

Lin, H.-C., Chen, Y.-F., Hsu, W.-H., Yang, C.-W., Kao, C.-H., and Tsai, T.-F. Resveratrol Helps Recovery from Fatty Liver and Protects against Hepatocellular Carcinoma Induced by Hepatitis B Virus X Protein in a Mouse Model. Cancer Prevention Research. 2012;5(7):952–62

Liu, J., Lin, H., and McIntosh, H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J. Viral Hepat. 2001;8(5):358–66

Loo, W. T. Y., Cheung, M. N. B., and Chow, L. W. C. Fructusschisandrae (Wuweizi)-containing compound inhibits secretion of HBsAg and HBeAg in hepatocellular carcinoma cell line. Biomed Pharmacother. 2007;61(9):606–10

Ma, W.-H., Huang, H., Zhou, P., and Chen, D.-F.Schisanwilsonenes A-C, anti-HBV Carotanesesquiterpenoids from the fruits of Schisandrawilsoniana. J. Nat. Prod. 2009a;72(4):676–8

Ma, W.-H., Lu, Y., Huang, H., Zhou, P., and Chen, D.-F.Schisanwilsonins A-G and related anti-HBV lignans from the fruits of Schisandrawilsoniana.Bioorg. Med. Chem. Lett. 2009b;19(17):4958–62

Mandel, S., Amit, T., Reznichenko, L., Weinreb, O., and Youdim, M. B. H. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol. Nutr. Food Res. 2006;50(2):229–34

Mao, H.-Y., and Shi, T.-D. [Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis]. ZhonghuaGanZang Bing ZaZhi. 2011;19(1):29–33

Marieb, E., and Hoehn, K. Human anatomy & physiology. 8th ed. San Francisco: Pearson Benjamin Cummings. 2010.

Marion, S. A., TommPastore, M., Pi, D. W., and Mathias, R. G. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am. J. Epidemiol. 1994;140(8):734–46

Marshall, K. Therapeutic applications of whey protein.Altern Med Rev. 2004;9(2):136–56

Mayo Clinic.Cirrhosis.2011a Mayo Clinic. Available at: [Accessed August 26, 2012].

Mayo clinic.Hepatitis B. 2011b. Available at: [Accessed August 26, 2012].

Merck. Acute Viral Hepatitis: Hepatitis: Merck Manual Professional. 2007. Available at: [Accessed August 28, 2012].

Mitchell, A. E., Colvin, H. M., and Palmer Beasley, R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51(3):729–33

Mladěnka, P., Macáková, K., Filipský, T., et al.In vitro analysis of iron chelating activity of flavonoids. J. Inorg. Biochem. 2011;105(5):693–701

Monnier, L., Colette, C., Aguirre, L., and Mirouze, J. Evidence and mechanism for pectin-reduced intestinal inorganic iron absorption in idiopathic hemochromatosis.Am J ClinNutr. 1980;33(6):1225–32

Mutimer, D. J., and Lok, A. Management of HBV- and HCV-induced end stage liver disease. Gut. 2012;61Suppl 1:i59–67

Nebbia, G., Peppa, D., and Maini, M. K. Hepatitis B infection: current concepts and future challenges. QJM. 2012;105(2):109–13

Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids Plus N-Acetylcysteine in Severe Alcoholic Hepatitis. N Engl J Med. 2011;359(19):1781-9. Available at: Accessed August 30, 2012.

Nikolopoulos, G. K., Paraskevis, D., Hatzitheodorou, E., et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin. Infect. Dis. 2009;48(12):1763–71

Ozbal, E., Helvaci, M., Kasirga, E., Akdenizoğlu, F., and Kizilgüneşler, A. Serum zinc as a factor predicting response to interferon-alpha2b therapy in children with chronic hepatitis B. Biological Trace Element Research. 2002;90(1-3):31–8

Petrova, M., and Kamburov, V. Breastfeeding and chronic HBV infection: clinical and social implications. World J Gastroenterol. 2010;16(40):5042–6

Protzer, U., Maini, M. K., and Knolle, P. A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 2012;12(3):201–13

Rambaldi, A., Jacobs, B. P., Iaquinto, G., and Gluud, C. Milk Thistle for Alcoholic and/or Hepatitis B or C Liver Diseases-A Systematic Cochrane Hepato-Biliary Group Review with Meta-Analyses of Randomized Clinical Trials. Am J Gastroenterol. 2005;100(11):2583–91

Rauf, N., Tahir, S. S., Dilawar, S., Ahmad, I., and Parvez, S. Serum selenium concentration in liver cirrhotic patients suffering from hepatitis B and C in Pakistan.Biological Trace Element Research. 2012;145(2):144–50

Rechtman, M. M., Har-Noy, O., Bar-Yishay, I., et al. Curcumin inhibits hepatitis B virus via down-regulation of the metabolic coactivator PGC-1alpha. FEBS letters. 2010;584(11):2485–90

Rich, J. D., Ching, C. G., Lally, M. A., et al. A review of the case for hepatitis B vaccination of high-risk adults. Am. J. Med. 2003;114(4):316–8

Scaglione, S. J., and Lok, A. S. F. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142(6):1360–1

SciClone.Zadaxin Product Monograph. 2012:1–58

Shi, X.-F., Guo, S.-H., Wu, G., et al. [A multi-center clinical study of N-acetylcysteine on chronic hepatitis B].ZhonghuaGanZang Bing ZaZhi. 2005;13(1):20–3

Shimizu, I., Kohno, N., Tamaki, K., et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13(32):4295–305

Shohrati, M., Dermanaki, F., Babaei, F., and Alavian, S. M. Evaluation of the effects of oral N-acetylcysteine and a placebo in paraclinical and oxidative stress parameters of patients with chronic hepatitis B. Hepat Mon. 2010;10(2):95–100

Stray, S. J., Bourne, C. R., Punna, S., Lewis, W. G., Finn, M. G., and Zlotnick, A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. ProcNatlAcadSci USA. 2005;102(23):8138–43

Tang, L. L., Sheng, J. F., Xu, C. H., and Liu, K. Z. Clinical and experimental effectiveness of Astragali compound in the treatment of chronic viral hepatitis B. J. Int. Med. Res. 2009;37(3):662–7

Tanwar, S., and Dusheiko, G. Is there any value to hepatitis B virus genotype analysis? CurrGastroenterol Rep. 2012;14(1):37–46

TasdelenFisgin, N., Aydin, B. K., Sarikaya, H., et al. Oxidative stress and antioxidant defense in patients with chronic hepatitis B. Clin. Lab. 2012;58(3-4):273–80

Thephinlap, C., Phisalaphong, C., Lailerd, N., et al. Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids. Med Chem. 2011;7(1):62–9

Tohme, R. A., Ribner, B., Huey, M. J., and Spradling, P. R. Hepatitis B vaccination coverage and documented seroprotection among matriculating healthcare students at an academic institution in the United States. Infect Control HospEpidemiol. 2011;32(8):818–21

Varghese, L., Agarwal, C., Tyagi, A., Singh, R. P., and Agarwal, R. Silibinin efficacy against human hepatocellular carcinoma.Clin Cancer Res. 2005;11(23):8441–8

Wang, G.-F., Shi, L.-P., Ren, Y.-D., et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Res. 2009a;83(2):186–90

Wang, N., Shi, X.-F., Guo, S.-H., Zhang, D.-Z., and Ren, H. [A clinical study of N-acetylcysteine treatment in chronic hepatitis B patients].ZhonghuaGanZang Bing ZaZhi. 2008;16(7):487–9

Wang, S., Li, J., Huang, H., et al. Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali. Biol. Pharm. Bull. 2009b;32(1):132–5

Watanabe, A., Okada, K., Shimizu, Y., et al. Nutritional therapy of chronic hepatitis by whey protein (non-heated). J Med. 2000;31(5-6):283–302

Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E, . . . Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral research.May 2002;54(2):69-78.

Weidenbach, H., Orth, M., Adler, G., Mertens, T., and Schmid, R. M. Treatment of chronic hepatitis B with high-dose intravenous N-acetyl-L-cysteine.Hepatogastroenterology. 2003;50(54):2105–8

Weiss, L., Hildt, E., and Hofschneider, P. H. Anti-hepatitis B virus activity of N-acetyl-L-cysteine (NAC): new aspects of a well-established drug. Antiviral Res. 1996;32(1):43–53

Wilson, R., Purcell, D., Netter, H. J., and Revill, P. A. Does RNA interference provide new hope for control of chronic hepatitis B infection? Antivir.Ther.(Lond.). 2009;14(7):879–89

World Health Organization.Hepatitis B vaccines. Wkly. Epidemiol. Rec. 2009;84(40):405–19

Wu, M.-D., Huang, R.-L., Kuo, L.-M.Y., Hung, C.-C., Ong, C.-W., and Kuo, Y.-H.The anti-HBsAg (human type B hepatitis, surface antigen) and anti-HBeAg (human type B hepatitis, e antigen) C18 dibenzocyclooctadienelignans from Kadsuramatsudai and Schizandraarisanensis. Chem. Pharm. Bull. 2003;51(11):1233–6

Wu, Y.-F., Fu, S.-L., Kao, C.-H., et al. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res. 2008;68(6):2033–42

Xia, Y., Luo, H., Liu, J. P., and Gluud, C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database Syst Rev. 2011;(4):CD008960

Xu, J., Wang, J., Deng, F., Hu, Z., and Wang, H. Green tea extract and its major component epigallocatechingallate inhibits hepatitis B virus in vitro. Antiviral Res. 2008;78(3):242–9

Xu, M., Wang, B., Fu, Y., et al. Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease. Microb. Ecol. 2012;63(2):304–13

Yang, Y.-F., Zhao, W., Zhong, Y.-D., et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res. 2008;77(2):136–41

Yip, A. Y. S., Loo, W. T. Y., and Chow, L. W. C. FructusSchisandrae (Wuweizi) containing compound in modulating human lymphatic system - a Phase I minimization clinical trial. Biomed Pharmacother. 2007;61(9):588–90

Yu, S. Y., Zhu, Y. J., and Li, W. G. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biological Trace Element Research. 1997;56(1):117–24

Yuan, J. M., Ross, R. K., Stanczyk, F. Z., et al. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China.Int J Cancer. 1995;63(4):491–3

Zhang, Y.-Y., Chen, E.-Q., Yang, J., Duan, Y.-R., and Tang, H. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol. J. 2009;6:63.